CG Oncology Announces…

Home PRESS RELEASE CG Oncology Announces First Patient Dosed in Phase 2 Clinical Trial of cretostimogene grenadenorepvec, an Oncolytic Immunotherapy, in Combination with pembrolizumab for Non-Muscle-Invasive Bladder Cancer Unresponsive to Bacillus Calmette-Guerin 💻...

CG Oncology Announces…

Home PRESS RELEASE CG Oncology Announces First Patient Dosed in Phase 1b Study of Oncolytic Immunotherapy cretostimogene grenadenorepvec in Combination with nivolumab in Muscle-Invasive Bladder Cancer 💻 DESKTOP AUDIO PLAYER =============================== --> Listen...

CG Oncology Announces…

Home PRESS RELEASE CG Oncology Announces License and Commercialization Agreement with Kissei Pharmaceutical Co., Ltd. for cretostimogene grenadenorepvec in Japan and Other Asian Countries 💻 DESKTOP AUDIO PLAYER =============================== --> Listen to this...

$22 Million Series…

Home PRESS RELEASE $22 Million Series C Financing 💻 DESKTOP AUDIO PLAYER =============================== --> Listen to this article now 0:00 📱 MOBILE AUDIO PLAYER =============================== --> Listen to this article now 0:00 0.5x 0.75x Normal 1.25x 1.5x 1.75x –...

Clinical Trial Collaboration…

Home PRESS RELEASE Clinical Trial Collaboration to Evaluate the Combination of cretostimogene grenadenorepvec and pembrolizumab in Bladder Cancer 💻 DESKTOP AUDIO PLAYER =============================== --> Listen to this article now 0:00 📱 MOBILE AUDIO PLAYER...

Clinical Results…

Home PRESS RELEASE Clinical Results at American Urological Association (AUA) Annual Meeting 2017 💻 DESKTOP AUDIO PLAYER =============================== --> Listen to this article now 0:00 📱 MOBILE AUDIO PLAYER =============================== --> Listen to this article...